Reference: https://pubmed.ncbi.nlm.nih.gov/39942639/
Resveratrol, a naturally occurring phenolic compound prevalent in foods such as grapes, berries, and peanuts, has garnered significant attention for its potential health benefits, including antioxidant and anti-inflammatory properties.
Research suggests that resveratrol may support cardiovascular health, protect cognitive function, and exhibit anticancer effects. However, its chemical structure is susceptible to alterations influenced by factors like pH levels, light exposure, specific enzymes, and metal ions, which can impact its stability and biological activity.
In their 2025 review published in Molecules, Ayoub Jaa and colleagues examine the transformation processes of resveratrol from its natural sources to human consumption. The authors delve into the mechanisms underlying resveratrol's chemical modifications, exploring how environmental conditions and biological systems can lead to the formation of various metabolites and polymers. These transformations are crucial, as they can significantly influence the compound's stability and bioactivity.
The review highlights that resveratrol exists in two isomeric forms: trans-resveratrol and cis-resveratrol. The trans form is more stable and predominantly found in nature, but it can isomerize to the cis form under certain conditions, such as exposure to ultraviolet light. This isomerization can alter resveratrol's biological efficacy, underscoring the importance of understanding the factors that influence its structural integrity.
Additionally, resveratrol can undergo oligomerization, leading to the formation of complex structures like δ-viniferin. These oligomers may possess distinct biological activities compared to monomeric resveratrol. The review discusses how such transformations can occur during food processing or within the human body, potentially affecting the health benefits associated with resveratrol consumption.
The authors also explore the impact of enzymatic activity on resveratrol metabolism. Enzymes present in the human gut microbiota can metabolize resveratrol into various derivatives, which may have different bioactivities and bioavailabilities. Understanding these metabolic pathways is essential for assessing the actual efficacy of resveratrol as a dietary supplement or therapeutic agent.
Furthermore, the review addresses the role of metal ions in resveratrol transformation. Metal ions can catalyze oxidative reactions, leading to the degradation of resveratrol or the formation of new compounds with altered biological properties. This aspect is particularly relevant in the context of food storage and processing, where metal-induced oxidation could diminish the health benefits of resveratrol-rich foods.
In summary, while resveratrol holds promise for various health applications, its propensity for chemical transformation poses challenges to its stability and efficacy. The review by Jaa et al. emphasizes the need for a comprehensive understanding of the mechanisms driving these transformations to optimize the beneficial effects of resveratrol in human health.
Future research should focus on developing strategies to preserve resveratrol's stability during food processing and within the human body to fully harness its therapeutic potential.
Reference: https://pubmed.ncbi.nlm.nih.gov/39956927/
Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide, encompassing conditions such as arrhythmias, coronary atherosclerotic heart disease, and hypertension. Resveratrol (RSV), a natural nonflavonoid phenolic compound, has garnered attention for its diverse biological activities, including antioxidant, anti-inflammatory, anticancer, and notably, cardiovascular protective effects.
Despite its therapeutic potential, RSV's clinical application is hindered by its susceptibility to oxidation and rapid metabolism, necessitating structural optimization to enhance its stability and efficacy.
In their 2025 review published in Archiv der Pharmazie, Yaling Peng and colleagues delve into the advancements concerning RSV and its derivatives in the context of CVDs. The authors systematically explore the synthesis of RSV derivatives, their structure-activity relationships, and the underlying mechanisms by which they exert cardiovascular protection. This comprehensive analysis aims to bridge the gap between RSV's promising pharmacological profile and its practical therapeutic application.
The review highlights various strategies employed to enhance RSV's bioavailability and stability. Chemical modifications, such as the introduction of methoxy groups or glycosylation, have been investigated to improve RSV's resistance to metabolic degradation. These structural alterations not only prolong the compound's half-life but also potentially augment its therapeutic potency against cardiovascular pathologies.
Furthermore, the authors discuss the mechanistic pathways through which RSV and its derivatives confer cardiovascular benefits. Key mechanisms include the attenuation of oxidative stress, modulation of inflammatory responses, and improvement of endothelial function. By scavenging reactive oxygen species and inhibiting pro-inflammatory mediators, RSV helps in preserving vascular integrity and preventing atherosclerotic developments.
The review also addresses the challenges and future directions in translating RSV research into clinical practice. Emphasis is placed on the need for extensive in vivo studies and clinical trials to validate the efficacy and safety of optimized RSV derivatives. Additionally, exploring novel delivery systems, such as nanoparticle-based carriers, could further enhance the therapeutic potential of RSV in managing CVDs.
In summary, while RSV presents a promising natural compound for cardiovascular therapy, its clinical utility is limited by inherent instability and rapid metabolism. Advancements in chemical modification and a deeper understanding of its mechanistic actions offer a pathway to harnessing RSV's full therapeutic potential.
Ongoing research and development are crucial to overcoming existing limitations and facilitating the integration of RSV-based interventions into standard cardiovascular care.
Reference: https://www.nmn.com/news/new-harvard-study-shows-nmn-supplement-enhances-blood-vessel-formation
A collaborative study by researchers from Harvard Medical School, Princeton University, and institutions in Switzerland has revealed that nicotinamide mononucleotide (NMN), a precursor to NAD+ (nicotinamide adenine dinucleotide), plays a critical role in combating age-related decline in blood vessel formation.
The research highlights NMN's potential in rejuvenating the vascular system, which tends to lose its regenerative ability with age.
Key findings of the study include:
This research underscores the broader potential of NMN in age-related health interventions, particularly in improving circulation, promoting tissue repair, and maintaining overall cardiovascular health.
It also opens the door for further exploration into combined therapies that leverage NMN with other natural compounds for enhanced efficacy in slowing or reversing aspects of the aging process.
Reference: https://www.nmn.com/news/nmn-protects-against-colon-cancer-new-study-finds
A recent study has highlighted the potential of nicotinamide mononucleotide (NMN) in preventing colon cancer. Researchers utilised a mouse model, inducing colon tumors through a combination of azoxymethane injections and dextran sulfate sodium to simulate inflammation-driven carcinogenesis.
Mice treated with NMN exhibited a significant reduction in tumor formation compared to their untreated counterparts, suggesting NMN's protective role against colon cancer development.
The study delved into the mechanisms behind NMN's protective effects, focusing on its impact on oxidative stress and inflammation—both key contributors to tumorigenesis. Untreated mice displayed elevated markers of DNA-damaging oxidative stress and inflammation within their colon tissues. In contrast, NMN-treated mice showed markedly lower levels of these harmful markers, indicating that NMN effectively mitigates gut inflammation and oxidative stress.
These findings suggest that NMN's antioxidative and anti-inflammatory properties play a crucial role in its ability to suppress tumor development in the colon.
While these preclinical results are promising, further research is necessary to determine the applicability of NMN as a preventive or therapeutic agent for colon cancer in humans.
Future studies should aim to explore the optimal dosing, safety, and efficacy of NMN in clinical settings, as well as its potential interactions with existing cancer treatments.
Reference: https://www.nmn.com/news/nmn-suppresses-the-progression-of-hearing-loss-new-research-from-japan-show
A recent study conducted by researchers at the Wellness Science Laboratory in Japan has demonstrated that nicotinamide mononucleotide (NMN) supplementation can prevent age-related hearing loss in mice.
The study observed that older mice exhibited higher auditory brainstem response (ABR) thresholds compared to younger mice, indicating hearing impairment. However, when 12-week-old mice were administered NMN at a dose of 500 mg/kg/day for 13 weeks, they maintained significantly lower ABR thresholds, suggesting that NMN effectively suppressed the progression of hearing loss.
Interestingly, the researchers did not observe a decline in NAD+ levels within the cochlea of the aged mice, which contrasts with previous studies showing reduced NAD+ levels in older mice. This discrepancy may be due to the relatively young age of the "aged" mice in the current study.
Additionally, NMN supplementation led to changes in gene expression related to ion homeostasis in the cochlea, implying that NMN may counteract age-related dysregulation of essential ions like iron and zinc in the inner ear.
While these findings are promising, translating them to human applications requires caution. Previous human studies have not shown significant improvements in hearing capacity with NMN supplementation, nor a correlation between blood NAD+ levels and hearing ability.
Therefore, further research is necessary to determine whether NMN can effectively mitigate age-related hearing loss in humans.
Reference: https://www.nmn.com/news/new-nad-world-3-0-theory-emphasizes-nmns-importance-in-aging
In February 2025, Dr. Shin-Ichiro Imai introduced the NAD World 3.0 theory, highlighting the pivotal role of nicotinamide mononucleotide (NMN) in the aging process. This updated model builds upon previous concepts by incorporating recent findings about NMN transport and synthesis.
Key Components of NAD World 3.0:
The NAD World 3.0 theory suggests that declining systemic NAD+ levels trigger an increase in Slc12a8 transporters in the small intestine. This upregulation enhances NMN uptake, subsequently boosting NAD+ synthesis to meet the body's demands. Through this mechanism, NMN is positioned as a crucial factor in maintaining NAD+ balance, thereby influencing the aging process.
This comprehensive framework offers a deeper understanding of how NMN and related pathways contribute to aging, potentially guiding future research and therapeutic strategies aimed at promoting healthy longevity.
